Volume : 12, Issue : 09, September – 2025
Title:
UPDATES IN THE MANAGEMENT OF STATUS EPILEPTICUS IN THE EMERGENCY DEPARTMENT:
A REVIEW OF EVIDENCE-BASED GUIDELINES AND NOVEL AGENTS
Authors :
Ahmad Ali Albarakati, Abdulrahman Hussain Althbyani, Adel Manee Yahya Alomari, Arif Saleh Nimran Al Sharyah, Ahmed Ali Ahmed Alshihabi, Mohsen Hassan Almalki, Ali Alhassan Ali Almehdawi, Hasen Hussain Alzahrani, Maqbool Hassan Almalki, Ali Mohammed Almahdawi
Abstract :
Status epilepticus (SE) is a time-critical neurological emergency associated with significant morbidity and mortality, requiring prompt and structured management in the emergency department (ED). This narrative review synthesizes the current evidence and recent advancements in the management of SE, with a particular focus on updates to evidence-based guidelines and the integration of novel pharmacological agents. A systematic literature search was conducted using PubMed, MEDLINE, Scopus, and Cochrane databases for articles published between 2013 and 2024, alongside seminal earlier works. The review outlines the imperative for rapid stabilization and the unchallenged role of benzodiazepines as first-line therapy, emphasizing the importance of non-IV formulations like intramuscular and intranasal midazolam to reduce time-to-treatment. It further explores the evolution of second-line therapy, where levetiracetam, valproate, and fosphenytoin are now established as equally effective options, enabling a more personalized approach to care. The management of refractory and super-refractory SE is discussed, highlighting the critical role of continuous EEG monitoring and the emerging use of ketamine to overcome GABAergic resistance. Furthermore, the review addresses the diagnostic challenges of nonconvulsive SE and adaptations required for special populations. By comparing guidelines from the American Epilepsy Society and the Neurocritical Care Society, this paper provides a clear roadmap for ED clinicians, reconciling differences and underscoring the principle that “time is brain.” Finally, we conclude by identifying key challenges and future directions for research, including the optimization of protocols, the need for prospective trials on novel agents, and the move towards personalized medicine in SE management.
Keywords: Status Epilepticus; Emergency Department; Management; Guidelines; Benzodiazepines; Neurological Emergency
Cite This Article:
Please cite this article in press Ahmad Ali Albarakati et al., Updates in the Management Of Status Epilepticus In The Emergency Department: A Review Of Evidence-Based Guidelines And Novel Agents., Indo Am. J. P. Sci, 2025; 12(09).
REFERENCES:
1. Al-Mufti, F., & Claassen, J. (2014). Neurocritical care: Status epilepticus review. Critical Care Clinics, *30*(4), 751–764. https://doi.org/10.1016/j.ccc.2014.06.006
2. Battino, D., et al. (2021). Management of epilepsy in pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disorders.
3. Betjemann, J. P., & Lowenstein, D. H. (2015). Status epilepticus in adults. The Lancet Neurology, *14*(6), 615–624. https://doi.org/10.1016/S1474-4422(15)00042-3
4. Brigo, F., Bragazzi, N. L., Bacigaluppi, S., Nardone, R., & Trinka, E. (2021). Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials. Epilepsy & Behavior, *114*(Pt A), 107611. https://doi.org/10.1016/j.yebeh.2020.107611
5. Brophy, G. M., Bell, R., Claassen, J., Alldredge, B., Bleck, T. P., Glauser, T., Laroche, S. M., Riviello, J. J., Jr, Shutter, L., Sperling, M. R., Treiman, D. M., & Vespa, P. M. (2012). Guidelines for the evaluation and management of status epilepticus. Neurocritical Care, *17*(1), 3–23. https://doi.org/10.1007/s12028-012-9695-z
6. Fang, Y., & Wang, X. (2015). Ketamine for the treatment of refractory status epilepticus. Seizure, *30*, 14–20. https://doi.org/10.1016/j.seizure.2015.05.010
7. Fodale, V., et al. (2022). Propofol infusion syndrome: A structured narrative review and analysis of pharmacovigilance data. CNS Drugs.
8. Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., Jagoda, A., Lowenstein, D., Pellock, J., Riviello, J., Sloan, E., & Treiman, D. M. (2016). Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents, *16*(1), 48–61. https://doi.org/10.5698/1535-7597-16.1.48
9. Kapur, J., Elm, J., Chamberlain, J. M., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinzer, C., Cock, H., Fountain, N., Connor, J. T., Silbergleit, R., & NETT and PECARN Investigators. (2019). Randomized trial of three anticonvulsant medications for status epilepticus. The New England Journal of Medicine, 381(22), 2103–2113. https://doi.org/10.1056/NEJMoa1905795
10. Kapur, J., et al. (2019). Randomized trial of three anticonvulsant medications for status epilepticus. New England Journal of Medicine.
11. Rosati, A., Ilvento, L., L’Erario, M., De Masi, S., & Bianchi, R. (2018). Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology, *91*(7), e666–e674. https://doi.org/10.1212/WNL.0000000000005994
12. Rösche, J., Kampf, C., Benecke, R., & Rösche, B. (2020). Efficacy and tolerability of levetiracetam, lacosamide and valproate in patients with status epilepticus: A systematic review and meta-analysis. Seizure, *81*, 169–177. https://doi.org/10.1016/j.seizure.2020.08.007
13. Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., & Barsan, W. (2012). Intramuscular versus intravenous therapy for prehospital status epilepticus. The New England Journal of Medicine, 366(7), 591–600. https://doi.org/10.1056/NEJMoa1107494
14. Silbergleit, R., et al. (2012). Intramuscular versus intravenous therapy for prehospital status epilepticus. New England Journal of Medicine.
15. Strzelczyk, A., et al. (2017). Lacosamide in status epilepticus: A systematic review of the literature. Epilepsy & Behavior.
16. Strzelczyk, A., Zöllner, J. P., Willems, L. M., Jost, J., Paule, E., Schubert-Bast, S., & Rosenow, F. (2017). Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia, 58(6), 933–950. https://doi.org/10.1111/epi.13716
17. Sutter, R., et al. (2020). Nonconvulsive status epilepticus in adults: A diagnostic and therapeutic overview. Lancet Neurology.
18. Sutter, R., Rüegg, S., & Tschudin-Sutter, S. (2020). Seizures as adverse events of antibiotic drugs: A systematic review. Neurology, 95(12), 544–556. https://doi.org/10.1212/WNL.0000000000010107
19. Tabernero, A., et al. (2021). Status epilepticus: A contemporary review. Current Neurology and Neuroscience Reports.
20. Trinka, E., & Höfler, J. (2022). The pharmacology of status epilepticus and refractory status epilepticus. Current Opinion in Pharmacology, *64*, 102221. https://doi.org/10.1016/j.coph.2022.102221
21. Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015). A definition and classification of status epilepticus–Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia, *56*(10), 1515–1523. https://doi.org/10.1111/epi.13121